123 related articles for article (PubMed ID: 25224251)
1. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.
Zhao N; Wilkerson MD; Shah U; Yin X; Wang A; Hayward MC; Roberts P; Lee CB; Parsons AM; Thorne LB; Haithcock BE; Grilley-Olson JE; Stinchcombe TE; Funkhouser WK; Wong KK; Sharpless NE; Hayes DN
Lung Cancer; 2014 Nov; 86(2):255-61. PubMed ID: 25224251
[TBL] [Abstract][Full Text] [Related]
2. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
[TBL] [Abstract][Full Text] [Related]
4. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract][Full Text] [Related]
5. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide analysis of survival in early-stage non-small-cell lung cancer.
Huang YT; Heist RS; Chirieac LR; Lin X; Skaug V; Zienolddiny S; Haugen A; Wu MC; Wang Z; Su L; Asomaning K; Christiani DC
J Clin Oncol; 2009 Jun; 27(16):2660-7. PubMed ID: 19414679
[TBL] [Abstract][Full Text] [Related]
7. The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.
Rackley B; Seong CS; Kiely E; Parker RE; Rupji M; Dwivedi B; Heddleston JM; Giang W; Anthony N; Chew TL; Gilbert-Ross M
Commun Biol; 2021 Jan; 4(1):142. PubMed ID: 33514834
[TBL] [Abstract][Full Text] [Related]
8. Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.
Newnham GM; Conron M; McLachlan S; Dobrovic A; Do H; Li J; Opeskin K; Thompson N; Wright GM; Thomas DM
BMC Cancer; 2011 Mar; 11():93. PubMed ID: 21385341
[TBL] [Abstract][Full Text] [Related]
9. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
Gao Y; Ge G; Ji H
Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
[TBL] [Abstract][Full Text] [Related]
10. Genetic profiles of oligometastatic non-small-cell lung cancer and corresponding brain metastases.
Werner RS; Rechsteiner M; Moch H; Curioni-Fontecedro A; Weller M; Weiss T; Regli L; Le Rhun E; Mairinger F; Opitz I; Soltermann A
Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38796684
[TBL] [Abstract][Full Text] [Related]
11. CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype.
Duregon E; Senetta R; Pittaro A; Verdun di Cantogno L; Stella G; De Blasi P; Zorzetto M; Mantovani C; Papotti M; Cassoni P
Oncotarget; 2015 Oct; 6(30):29626-36. PubMed ID: 26315660
[TBL] [Abstract][Full Text] [Related]
12. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.
Yuan T; Zeng C; Liu J; Zhao C; Ge F; Li Y; Qian M; Du J; Wang W; Li Y; Liu Y; Dai X; Zhou J; Chen X; Ma S; Zhu H; He Q; Yang B
Signal Transduct Target Ther; 2024 Jan; 9(1):11. PubMed ID: 38177135
[TBL] [Abstract][Full Text] [Related]
13. Integrating image and gene-data with a semi-supervised attention model for prediction of KRAS gene mutation status in non-small cell lung cancer.
Xue Y; Zhang D; Jia L; Yang W; Zhao J; Qiang Y; Wang L; Qiao Y; Yue H
PLoS One; 2024; 19(3):e0297331. PubMed ID: 38466735
[TBL] [Abstract][Full Text] [Related]
14. LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
Lagoudaki ED; Koutsopoulos AV; Sfakianaki M; Papadaki C; Manikis GC; Voutsina A; Trypaki M; Tsakalaki E; Fiolitaki G; Hatzidaki D; Yiachnakis E; Koumaki D; Mavroudis D; Tzardi M; Stathopoulos EN; Marias K; Georgoulias V; Souglakos J
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791897
[TBL] [Abstract][Full Text] [Related]
15. CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
Bai Y; Liu Y; Wu J; Miao R; Xu Z; Hu C; Zhou J; Guo J; Xie J; Shi Z; Ding X; Xing Y; Hu D
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16827-16836. PubMed ID: 37733240
[TBL] [Abstract][Full Text] [Related]
16. Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
Koo J; Seong CS; Parker RE; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C; Ramalingam SS; Fu H; Zhou W; Marcus AI; Gilbert-Ross M
bioRxiv; 2023 Jun; ():. PubMed ID: 37398244
[TBL] [Abstract][Full Text] [Related]
17. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.
Lee HM; Muhammad N; Lieu EL; Cai F; Mu J; Ha YS; Cao G; Suchors C; Joves K; Chronis C; Li K; Ducker GS; Olszewski K; Cai L; Allison DB; Bachert SE; Ewing WR; Wong H; Seo H; Kim IY; Faubert B; Kim J; Kim J
Nat Metab; 2024 Jun; ():. PubMed ID: 38877143
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide integrative analysis revealed a correlation between lengths of copy number segments and corresponding gene expression profile.
Miyaguchi K; Fukuoka Y; Mizushima H; Yasen M; Nemoto S; Ishikawa T; Uetake H; Tanaka S; Sugihara K; Arii S; Tanaka H
Bioinformation; 2011; 7(6):280-4. PubMed ID: 22355221
[TBL] [Abstract][Full Text] [Related]
19. Comments on 'Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer'.
Tong X; Zhang N; Xue Y; Ji H
J Mol Cell Biol; 2024 Mar; ():. PubMed ID: 38553961
[No Abstract] [Full Text] [Related]
20. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
